Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576567 | 1.00 | AOC3 (0.34) | AOC3MAOBCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL14576565 | 1.00 | AOC3 (0.34) | AOC3MAOBCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL14616283 | 0.89 | AOC3 (0.34) | AOC3MAOB | |
| SCHEMBL14576007 | 0.84 | BTN3A1 (0.33) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1443819 | 0.84 | BTN3A1 (0.33) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL10002548 | 0.84 | CYP3A4 (0.34) | AOC3MAOBCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9734896 | 0.83 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9734890 | 0.83 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1444897 | 0.80 | AOX1 (0.34) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9150610 | 0.78 | HDAC3 (0.33) | CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | Epiphany Biosciences ,Inc. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2470194-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | Epiphany Biosciences Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011031567-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | EPIPHANY BIOSCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | PNP, TYMP, ENTPD5 | AOC3 4827/4885MAOB 4332/4885CYP3A4 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.